UOC
ABOS icon

UBS O'Connor’s Acumen Pharmaceuticals ABOS Stock Holding History

UBS O'Connor’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-69,538
Closed -$289K – 505
2023
Q3 		$289K Sell
69,538
-10,000
-13% -$61.8K 0.01% 434
2023
Q2 		$383K Buy
79,538
+18,180
+30% +$87K 0.01% 461
2023
Q1 		$249K Buy
+61,358
New +$320K 0.01% 504

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS O'Connor's ABOS Position: Q4 2023 in Review

UBS O'Connor sold out of Acumen Pharmaceuticals (ABOS) in Q4 2023, closing a stake of 69,538 shares — an estimated $289K sold.

UBS O'Connor first reported a position in ABOS in Q1 2023 and held it in 3 quarters. The position peaked at $383K in Q2 2023. 67 funds tracked by Wall St. Rank hold ABOS as of Q4 2023.

  • UBS O'Connor reported no remaining Acumen Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • UBS O'Connor sold 69,538 Acumen Pharmaceuticals shares in Q4 2023, an estimated $289K.
  • UBS O'Connor first reported a position in Acumen Pharmaceuticals in Q1 2023 and held it in 3 quarters.
  • UBS O'Connor's Acumen Pharmaceuticals position peaked at $383K in Q2 2023.
  • 67 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q4 2023.

Based on UBS O'Connor's 13F filing for Q4 2023, filed 14 Feb 2024.